The significance of chronic kidney disease, heart failure and cardiovascular disease for mortality in type 1 diabetes: nationwide observational study

被引:0
|
作者
Björn Eliasson
Lovisa Lyngfelt
Sven-Olof Strömblad
Stefan Franzén
Katarina Eeg-Olofsson
机构
[1] Sahlgrenska University Hospital,Department of Medicine
[2] Centre of Registries in Region Western Sweden,National Diabetes Register
[3] University of Gothenburg,Institute of Medicine
[4] Sahlgrenska University Hospital,Primary Care Global Business Unit
[5] Sanofi,Health Metrics, School of Public Health and Community Medicine
[6] University of Gothenburg,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
People with type 1 diabetes have a substantially increased risk of premature death. This nationwide, register-based cohort study evaluated the significance of risk factors and previous cardiovascular disease (CVD), heart failure and chronic kidney disease (CKD), for mortality in type 1 diabetes. Nationwide, longitudinal, register-based cohort study. Patients (n = 36,303) listed in the Swedish National Diabetes Register between January 1 2015 and December 31 2017 were included and followed until December 31, 2018. Data were retrieved from national health registries through each patient's unique identifier, to capture data on clinical characteristics, outcomes, or deaths, to describe mortality rates in risk groups. The mean follow-up time was 3.3 years, with 119,800 patient years of observation and 1127 deaths, corresponding to a crude overall mortality of 0.92% deaths/year. Statistically significant increased risk in multivariate analyzes was found in older age groups, in men, and in underweight or people with normal BMI, high HbA1c or blood pressure. A history of CVD, albuminuria and advanced stages of CKD was associated with an increased risk of mortality. Each combination of these conditions further increased the risk of mortality. These results emphasize the importance of risk factors and cardiovascular and renal diabetes complications. People with a combination of CKD, CVD, and heart failure, exhibit a markedly increased risk of dying prematurely. These findings provide strong arguments for optimized and individualized treatment of these groups of people with type 1 diabetes in clinical everyday life.
引用
收藏
相关论文
共 50 条
  • [1] The significance of chronic kidney disease, heart failure and cardiovascular disease for mortality in type 1 diabetes: nationwide observational study
    Eliasson, Bjorn
    Lyngfelt, Lovisa
    Stromblad, Sven-Olof
    Franzen, Stefan
    Eeg-Olofsson, Katarina
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [2] Cardiovascular mortality in patients with advanced chronic kidney disease with and without diabetes: a nationwide cohort study
    Dea Haagensen Kofod
    Nicholas Carlson
    Ellen Freese Ballegaard
    Thomas Peter Almdal
    Christian Torp-Pedersen
    Gunnar Gislason
    Jesper Hastrup Svendsen
    Bo Feldt-Rasmussen
    Mads Hornum
    Cardiovascular Diabetology, 22
  • [3] Cardiovascular mortality in patients with advanced chronic kidney disease with and without diabetes: a nationwide cohort study
    Kofod, Dea Haagensen
    Carlson, Nicholas
    Ballegaard, Ellen Freese
    Almdal, Thomas Peter
    Torp-Pedersen, Christian
    Gislason, Gunnar
    Svendsen, Jesper Hastrup
    Feldt-Rasmussen, Bo
    Hornum, Mads
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [4] Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes
    Vaduganathan, Muthiah
    Filippatos, Gerasimos
    Claggett, Brian L.
    Desai, Akshay S.
    Jhund, Pardeep S.
    Henderson, Alasdair
    Brinker, Meike
    Kolkhof, Peter
    Schloemer, Patrick
    Lay-Flurrie, James
    Viswanathan, Prabhakar
    Lam, Carolyn S. P.
    Senni, Michele
    Shah, Sanjiv J.
    Voors, Adriaan A.
    Zannad, Faiez
    Rossing, Peter
    Ruilope, Luis M.
    Anker, Stefan D.
    Pitt, Bertram
    Agarwal, Rajiv
    Mcmurray, John J. V.
    Solomon, Scott D.
    NATURE MEDICINE, 2024, 30 (12) : 3778 - 3778
  • [5] TYPE 2 DIABETES, CHRONIC KIDNEY DISEASE, AND MORTALITY IN PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE
    Saely, Christoph
    Vonbank, Alexander
    Lins, Christina
    Zanolin, Daniela
    Leiherer, Andreas
    Rein, Philipp
    Muendlein, Axel
    Drexel, Heinz
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 1841 - 1841
  • [6] Type 2 diabetes, chronic kidney disease, and mortality in patients with established cardiovascular disease
    Saely, Christoph
    Vonbank, Alexander
    Lins, Christina
    Zanolin, Daniela
    Leiherer, Andreas
    Schuler, Alexandra
    Ebner, Karl-Martin
    Rein, Philipp
    Schwerzler, Peter
    Mader, Arthur
    Muendlein, Axel
    Drexel, Heinz
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 : S128 - S128
  • [7] Type 2 diabetes, chronic kidney disease, and mortality in patients with established cardiovascular disease
    Saely, C. H.
    Vonbank, A.
    Lins, C.
    Zanolin, D.
    Leiherer, A.
    Schuler, A.
    Schwerzler, P.
    Mader, A.
    Rein, P.
    Muendlein, A.
    Drexel, H.
    EUROPEAN HEART JOURNAL, 2017, 38 : 324 - 324
  • [8] Type 2 diabetes, chronic kidney disease, and mortality in patients with established cardiovascular disease
    Saely, C. H.
    Vonbank, A.
    Lins, C.
    Zanolin, D.
    Leiherer, A.
    Mader, A.
    Larcher, B.
    Muendlein, A.
    Drexel, H.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2018, 48 : 156 - 156
  • [9] Type 2 diabetes, chronic kidney disease, and mortality in patients with established cardiovascular disease
    Saely, Christoph
    Vonbank, Alexander
    Lins, Christina
    Zanolin, Daniela
    Leiherer, Andreas
    Ebner, Karl-Martin
    Schwerzler, Peter
    Mader, Arthur
    Heinzle, Christine
    Muendlein, Axel
    Drexel, Heinz
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 : 170 - 170
  • [10] TYPE 2 DIABETES, CHRONIC KIDNEY DISEASE, AND MORTALITY IN PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE
    Saely, C. H.
    Vonbank, A.
    Lins, C.
    Zanolin, D.
    Leiherer, A.
    Mader, A.
    Larcher, B.
    Muendlein, A.
    Drexel, H.
    ATHEROSCLEROSIS, 2018, 275 : E202 - E203